Cynapsus Therapeutic (CYNAF) 0.9370 $CYNAF First patient

New Post Public Reply Private Reply Replies (0) Message Board

Jul 11, 2015 at 8:57 AM

Cynapsus Therapeutic (CYNAF) 0.9370 $CYNAF

First patient enrolled in late stage study of Cynapsus Therapeutics' Parkinson's candidate
Seeking Alpha - at Seeking Alpha - Mon Jun 29, 6:41AM CDT

Cynapsus Therapeutics Inc. : Announces Proposed Public Offering in the United States, Listing on NASDAQ and Share Consolidation
GlobeNewswire - Fri May 15, 4:33PM CDT
Cynapsus Therapeutics Inc. (TSX: CTH) (OTCQX: CYNAF) announced today the filing of a registration statement with the US Securities and Exchange Commission relating to a public offering in the United States of its common shares and the filing of an application to list on the NASDAQ Capital Market. The timing, number of shares and price per share of the proposed offering have not yet been determined. Cynapsus also announced an amendment to the Company's articles to consolidate the issued and outstanding common shares of the Company on the basis of one post-consolidation common share for 16 pre-consolidation common shares to facilitate the proposed listing on NASDAQ, as previously approved by the shareholders of the Company.
CTH.TO: 21.46 (+0.46)

Cynapsus Therapeutics Announces Proposed Public Offering in the United States, Listing on NASDAQ and Share Consolidation
Marketwired - Fri May 15, 4:29PM CDT
Cynapsus Therapeutics Inc. (TSX: CTH)(OTCQX: CYNAF) announced today the filing of a registration statement with the US Securities and Exchange Commission relating to a public offering in the United States of its common shares and the filing of an application to list on the NASDAQ Capital Market. The timing, number of shares and price per share of the proposed offering have not yet been determined. Cynapsus also announced an amendment to the Company's articles to consolidate the issued and outstanding common shares of the Company on the basis of one post-consolidation common share for 16 pre-consolidation common shares to facilitate the proposed listing on NASDAQ, as previously approved by the shareholders of the Company.
CTH.TO: 21.46 (+0.46)

Cynapsus Therapeutics Inc. : Reports First Quarter 2015 Financial Results and Recent Developments
GlobeNewswire - Fri May 08, 3:54PM CDT
Cynapsus Therapeutics Inc. (TSX: CTH) (OTCQX: CYNAF), a specialty Central Nervous System (CNS) pharmaceutical company developing and preparing to commercialize a fast-acting, easy-to-use sublingual thin film for the on-demand management of debilitating OFF episodes associated with Parkinson's disease (PD), today announced financial results for the three months ended March 31, 2015. Unless specified otherwise, all amounts are in Canadian dollars.
CTH.TO: 21.46 (+0.46)

Cynapsus Therapeutics Reports First Quarter 2015 Financial Results and Recent Developments
Marketwired - Fri May 08, 3:46PM CDT
Cynapsus Therapeutics Inc. (TSX: CTH)(OTCQX: CYNAF), a specialty Central Nervous System (CNS) pharmaceutical company developing and preparing to commercialize a fast-acting, easy-to-use sublingual thin film for the on-demand management of debilitating OFF episodes associated with Parkinson's disease (PD), today announced financial results for the three months ended March 31, 2015. Unless specified otherwise, all amounts are in Canadian dollars.
CTH.TO: 21.46 (+0.46)

Cynapsus Therapeutics Announces CAD$21 Million Private Placement
Business Wire - Tue Mar 31, 9:26AM CDT
Cynapsus Therapeutics Inc. (TSX:CTH) (OTCQX:CYNAF), a specialty pharmaceutical company focused on the treatment of OFF episodes in Parkinson's disease, today announced the completion of a private placement (the "Offering"

of 22,039,472 common shares of the Company (the "Common Shares"

for gross proceeds of CAD$20,981,579.
CTH.TO: 21.46 (+0.46)

Cynapsus Therapeutics Reports 2014 Annual Results
Business Wire - Tue Mar 17, 4:56PM CDT
Cynapsus Therapeutics Inc. (TSX:CTH) (OTCQX:CYNAF), a specialty pharmaceutical company focused on the treatment of OFF episodes in Parkinson's disease, today announced financial results for the year ended December 31, 2014. Unless specified otherwise, all amounts are in Canadian dollars.
CTH.TO: 21.46 (+0.46)

Cynapsus to Host Analyst and Investor Breakfast in New York City on March 18
Business Wire - Mon Mar 16, 5:00AM CDT
Cynapsus Therapeutics Inc. (TSX:CTH) (OTCQX:CYNAF), a specialty pharmaceutical company focused on Parkinson's disease, announced that it will host an Analyst and Investor Breakfast featuring presentations by executive management and a clinical key opinion leader on Wednesday, March 18, 2015 at 7:30 a.m. in New York City.
CTH.TO: 21.46 (+0.46)

Cynapsus Therapeutics Appoints Tamar Howson to Board of Directors
Business Wire - Thu Mar 12, 3:10PM CDT
Cynapsus Therapeutics Inc. (TSX:CTH) (OTCQX:CYNAF), a specialty pharmaceutical company focused on the treatment of OFF episodes in Parkinson's disease, today announced that Tamar Howson has been appointed to the Company's Board of Directors. With the addition of Ms. Howson to the Board of Directors, the Company now has eight directors, with seven directors classified as independent.
OXGN: 1.39 (+0.07), NPSP: 45.97 (+0.01), BMY: 69.27 (+1.38), CTH.TO: 21.46 (+0.46)

Cynapsus Therapeutics to start Phase 3 trial for Parkinson's drug in Q2
Seeking Alpha - at Seeking Alpha - Wed Mar 11, 4:08PM CDT

Cynapsus Therapeutics Provides Clinical and Regulatory Update for APL-130277 for the Acute Rescue of OFF Motor Symptoms of Parkinson's Disease
Business Wire - Wed Mar 11, 3:10PM CDT
--Received Final Minutes From End-of-Phase 2 Meeting with U.S. FDA
CTH.TO: 21.46 (+0.46)

New Parkinson's drug cleared in Europe
Seeking Alpha - at Seeking Alpha - Thu Feb 26, 9:23AM CST

ADMS: 27.41 (+0.83), ACOR: 34.07 (+0.65), NDRM: 15.62 (+1.27), XNPT: 6.79 (+0.16), IPXL: 47.36 (+1.35), ABBV: 69.23 (+1.26), TEVA: 61.38 (-0.75), SNY: 51.49 (+2.71), PRTA: 51.70 (+0.78)

Adamas' Lead Drug Targets Parkinson's Dyskinesia
Michael Hagan - at Seeking Alpha - Tue Feb 03, 4:53PM CST

IPXL: 47.36 (+1.35), ADMS: 27.41 (+0.83), ACOR: 34.07 (+0.65), NDRM: 15.62 (+1.27)

Cynapsus Therapeutics Inc. to Present at the D2 2015 - Noble Financial Capital Markets' Eleventh Annual Investor / Equity Conference
Business Wire - Thu Jan 15, 3:05PM CST
Cynapsus Therapeutics Inc. (TSX:CTH) (OTCQX:CYNAF), a specialty pharmaceutical company, today announced that its President and CEO, Anthony Giovinazzo, will present at the Noble Financial Capital Markets' Eleventh Annual Equity Conference at Club Med in Sandpiper Bay, Florida, on Monday, January 19th at 10:00am Eastern Standard Time in Room 1.
CTH.TO: 21.46 (+0.46)

Medical Marijuana Goes To Market: Daniel Pearlstein Of M Partners
Life Sciences Report - at Seeking Alpha - Thu Jan 08, 10:42AM CST
Life sciences analyst Daniel Pearlstein of Toronto-based M Partners brings knowledge of the biotech sector and hands-on experience in the startup realm to understanding value and growth in small- and micro-cap life sciences companies. In this...
MNK: 122.44 (+2.18), AUPH: 3.36 (-0.12), HZNP: 35.94 (+1.13), GSK: 42.45 (+0.65), BMY: 69.27 (+1.38)

15 Biotech Names For 2015
Jason Napodano, CFA - at Seeking Alpha - Mon Jan 05, 1:37PM CST

NBIX: 48.16 (+0.33), NVIV: 14.01 (-1.01), LPCN: 8.51 (+0.45), EPRS: 6.00 (+0.35), DEPO: 30.14 (+2.03), ASPX: 100.96 (unch), BCLI: 3.46 (-0.03), CUR: 1.69 (-0.01)

First patient enrolled in Acorda Phase 3 PD trial
Seeking Alpha - at Seeking Alpha - Wed Dec 10, 7:06AM CST

IPXL: 47.36 (+1.35), ADMS: 27.41 (+0.83), TEVA: 61.38 (-0.75), ACOR: 34.07 (+0.65), PRTA: 51.70 (+0.78), NDRM: 15.62 (+1.27)

Cynapsus Therapeutics Announces Uplisting to the Toronto Stock Exchange's Senior Equity Market
Business Wire - Tue Nov 25, 3:10PM CST
Cynapsus Therapeutics Inc. (TSX-V:CTH) (OTCQX:CYNAF), a specialty pharmaceutical company focused on Parkinson's disease, today announced that its common shares will commence trading on the Toronto Stock Exchange (TSX) as of the opening of trading on Friday, November 28, 2014. The Company's common shares will continue to trade under the symbol "CTH," with its common shares to cease trading on the TSX Venture Exchange concurrent with the commencement of trading on the TSX.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

PharmaBlock Forum: Strategic CMC Moves Crucial for Biotech

CMC Strategies: The Unsung Hero in Biotech Development Ah, the world of biotech, where one day you're a hero in the lab, and the next you're scrambling to make sense of chemistry, manufacturing, and controls (CMC). It's high time folks started realizing that CMC isn't just procedural drudgery—it's the backbone of making a promising drug go global. That's what the...

ASMAX Unleashes Next-Level Motorcycle Comms at EICMA

Transforming the Motorcycle Communication Landscape Motorcycling ain't just about the roaring engines and the rubber on the road. In the world of helmets and handlebars, some bright minds are weaving tech magic at the EICMA 2026 in Milan. ASMAX has rolled out its shiny new RoamX intercom gadget, leaving folks buzzing at Hall 6. What RoamX Brings to the Table This ain't...

Family-Run Pet Retailer Debuts in Alamo Ranch

Pet Supplies Plus Opens Its Doors in Alamo Ranch A fresh wave of pet-centered enthusiasm hit Alamo Ranch as Ray and Naz, proud local entrepreneurs, unveiled their new Pet Supplies Plus store on October 23. This isn't just any run-of-the-mill pet supply shop; it's a reflection of their personal journey as devoted pet parents. With a blend of grit and community spirit,...

Tigo Energy Faces Class Action: Investor Deadline Looms

Unpacking Tigo's Rollercoaster: Lawsuit & Market Reaction They sometimes say, "When it rains, it pours." For Tigo Energy, it’s been more a downpour than a drizzle. Here we are, chasing down what's going on with Tigo Energy (NASDAQ:TYGO), fresh off the heels of a class action fuss that's grabbed every investor's attention. If you've got a stake, or even a passing...

Valve Tool Innovation Streamlines Hydraulic Maintenance

A New Gadget Promises Big Savings in Time and Effort Ever wrestled with a hydraulic hose and felt like you were arm wrestling a gorilla? Well, it looks like there's a new gadget on the scene that might save you from that struggle. Straight from Menomonie, Wisconsin, we’ve got a slick new tool hitting the market called THE VALVE TOOL. The idea is simple but effective:...

SpaceMap Tackles Space Traffic With AI Innovation

SpaceMap Takes Aim at the Crowded Space Above You ever look up and wonder what's hurtling above our noggins? More satellites than you can shake a stick at, that's what. And don't even start me on the debris floating around. This ain't just rocket science anymore; it's a crowded dance floor, and someone's gotta manage it. Enter SpaceMap, a plucky South Korean startup that...

Laboratoires Pierre Fabre and XtalPi Unite for AI-Driven Drug Hunt

An Unexpected Turn in the Drug Discovery Arena It's not every day that you see a historic French pharma powerhouse and a cutting-edge Chinese tech firm join forces. On one side, we've got Laboratoires Pierre Fabre, steeped in the history and nitty-gritty of clinical drug development. On the other, we’ve got XtalPi Holdings Limited (2228.HK), bringing their high-tech AI...

PrimeFlight Welcomes CEO Amath Fall for Global Growth

A New Era Begins at PrimeFlight On a cloudy November morning in Sugar Land, Texas, some interesting news broke out of PrimeFlight Aviation Services. They've made what seems like a pivotal move by appointing Amath Fall as their new Chief Executive Officer, effective immediately. As PrimeFlight continues to elbow its way into new market territory, having someone like Fall...

Painter Capri: Comfort Revolution or Just Hype?

A New Hope for Painters' Comfort? Alright, here we go. Some folks out there in the land of ladders and rollers have had it with wearing uncomfortable, stifling work gear every day. Enter the PAINTER CAPRI. Designed by an inventive spirit from Homer Glen, Illinois, these pants aim to be both breathable and functionally sound—for painters, electricians, and other gritty...

Understanding Hired & Non-Owned Auto Insurance Basics

The Overlooked Gap in Auto Coverage Bet you didn't see this one coming: businesses often overestimate their auto insurance coverage, assuming their commercial policies cover all the bases. When employees drive personal vehicles for work purposes or when businesses borrow rides temporarily, these assumptions leave a gaping hole bigger than a sinkhole in a Florida street....